Grifols SA has demonstrated consistent revenue growth driven by its comprehensive plasma-derived therapies business, expanding from €4.9 billion in 2021 to €7.2 billion in 2024. Operational efficiency gains and a focused R&D approach helped offset margin pressures despite higher finance costs and rising tax rates in 2024. The company recently secured a strategic refinancing package extending debt maturities through 2033, reducing funded gross debt, and improving liquidity with leverage-based margin step-downs. Looking ahead, Grifols’ extensive plasma collection network and self-sufficiency programs position it well to capitalize on growing global demand, while management’s evaluation of a potential U.S. IPO for its Biopharma subsidiary signals an intent to unlock value amid ongoing capital discipline.